ClinicalTrials.gg
CompletedNCT02918279Updated Apr 27, 2020Results posted

Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

A Phase 3 interventional study of Liraglutide and Placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 33 sites in 5 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-04-27.

Primary conditionObesityRegistry: Nutrition DisordersReclassifiedWhy we changed it
Registry
Nutrition Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Nutrition Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 79 studies testing liraglutide in Obesity — 7 open to participants now, 9 under way, 2 of them phase 3. Liraglutide · Obesity.

Enrollment
14th of 79
251 · median 70
Started
2016
with 11 others
Phase 3
17 of 79
1 open now
Registered
29th of 79
by date
Lead sponsor
16 of 79
Novo Nordisk A/S

Among the 79 studies testing liraglutide in Obesity, this one is the 14th largest by enrollment, is one of 12 that started in 2016, is one of 17 in phase 3, and was the 29th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 79 studies testing liraglutide in Obesity are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies testing liraglutide in Obesity, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in pubertal adolescent subjects with obesity.

03

Conditions studied

  • Metabolism and Nutrition Disorder
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,547 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 251 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • Male or female, age 12 to less than 18 years at the time of signing informed consent and less than 18 years at date of randomisation
  • corresponding to equal to or above 30 kg/m\^2 for adults by international cut-off points and equal or above the 95th percentile for age and sex (for diagnosis of obesity)
  • Stable body weight during the previous 90 days before screening V2 (below 5 kg self-reported weight change)
  • History of failing to lose sufficient weight with lifestyle modification as judged by the investigator and documented in subject's medical record

Exclusion criteria

Exclusion Criteria:

  • Pre-pubertal subjects (Tanner stage 1) at screening V2
  • Type 1 diabetes mellitus (T1DM)
  • Family or personal history of multiple endocrine neoplasia type 2 (MEN2)
  • Medullary thyroid carcinoma (MTC)
  • History of pancreatitis (acute or chronic)
  • Subjects with secondary causes of obesity (i.e., hypothalamic, genetic or endocrine causes)
  • Treatment with medications within 90 days before screening V2 that, based on the investigator's judgement, may cause significant weight change. This should also include treatment with any of the following medications: pramlintide, orlistat, zonisamide, topiramate, lorcaserin, phenteremine, bupropion, naltrexone, glucagon-like peptide-1 (GLP-1) receptor agonists, or metformin (used as treatment for obesity)
  • Anti-diabetic treatment other than metformin
  • History of major depressive disorder within 2 years before screening V2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Liraglutide

    Drug: Liraglutide

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Administered once daily subcutaneously (s.c., under the skin)

  • DrugPlacebo

    Administered once daily subcutaneously (s.c., under the skin)

07

What researchers measure

Primary outcomes

  1. Change in BMI SDS (Week 0, Week 56)

    Change from baseline (week 0) in BMI SDS was evaluated at week 56. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the world health organisation (WHO) Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation. Results are based on both participants who completed the week 0-56 trial period and participants who prematurely discontinued the trial product but attended the follow-up visit at 56.

    Time frame: Week 0, week 56

Secondary outcomes

  1. Percent of Subjects Achieving ≥5% Reduction in Baseline BMI

    Participants achieving more than or equal to 5% reduction in their baseline (week 0) BMI was evaluated at weeks 30, 56 and 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

    Time frame: Weeks 30, 56 and 82

  2. Percent of Subjects Achieving ≥10% Reduction in Baseline BMI

    Participants achieving more than or equal to 10% reduction in their baseline (week 0) BMI was evaluated at weeks 30, 56 and 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

    Time frame: Weeks 30, 56 and 82

  3. Change in BMI SDS ((Week 0, Week 30); (Week 0, Week 82); (Week 56, Week 82))

    Change in BMI SDS was evaluated from baseline (week 0) to weeks 30 and 82, and from week 56 to week 82. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation. Results are based on both participants who completed the trial period, week 0-30 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30 or 82, respectively.

    Time frame: (Week 0, week 30); (Week 0, week 82); (Week 56, week 82)

  4. Change in BMI

    Change in BMI was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  5. Change in Body Weight (kg)

    Change in body weight (kg) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  6. Change in Body Weight (%)

    Relative change in body weight (kg) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  7. Change in Body Weight (lb)

    Body weight was not analysed in pounds (lb). It was analysed for standard unit, 'kg' only.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  8. Change in Waist Circumference

    Change in waist circumference was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  9. Change in Waist-to-hip Circumference Ratio

    Change in waist-to-hip circumference ratio was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  10. Change in hsCRP

    Change in high sensitivity C reactive protein (hsCRP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  11. Change in Fasting Lipid: Total Cholesterol (Ratio to Baseline)

    Change in total cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  12. Change in Fasting Lipid: LDL-cholesterol (Ratio to Baseline)

    Change in low density lipoprotein (LDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  13. Change in Fasting Lipid: HDL-cholesterol (Ratio to Baseline)

    Change in high density lipoprotein (HDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  14. Change in Fasting Lipid: Non-HDL Cholesterol (Ratio to Baseline)

    Change in non-HDL cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  15. Change in Fasting Lipid: VLDL Cholesterol (Ratio to Baseline)

    Change in very low density lipoprotein (VLDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  16. Change in Fasting Lipid: Triglycerides (Ratio to Baseline)

    Change in triglycerides from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  17. Change in Fasting Lipid: FFA (Ratio to Baseline)

    Change in free fatty acids (FFA) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  18. Change in Systolic and Diastolic Blood Pressure

    Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  19. Change in HbA1c

    Change in glycosylated haemoglobin (HbA1c) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  20. Change in FPG

    Change in fasting plasma glucose (FPG) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed treatment for the corresponding treatment period (week 0-30, week 0-56 or week 0-82).

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  21. Change in Fasting Insulin (Ratio to Baseline)

    Change in fasting insulin from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  22. Change in Fasting C-peptide (Ratio to Baseline)

    Change in fasting C-peptide from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  23. Change in Glycaemic Category

    Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes (T2DM)" at baseline (weeks -2), and weeks 30, 56 and 82 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes (T2DM): FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: Week -2, week 30, week 56 and week 82

  24. Change in HOMA-B (Ratio to Baseline)

    Change in homeostasis model assessment of beta-cell function (HOMA-B) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5). Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  25. Change in HOMA-IR (Ratio to Baseline)

    Change in homeostasis model assessment of insulin resistance (HOMA-IR) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting insulin \[mU/L\] x FPG \[mmol/L\]/ 22.5. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  26. Change in IWQOL-Kids

    Change in Impact of Weight on Quality of Life-Kids (IWQOL-Kids) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. The IWQOL-Kids is a 27-item measure of weight-related quality of life. There are four domain scores (Physical Comfort, Body Esteem, Social Life and Family Life) and a total score. Scores for all domains and total score range from 0-100, with higher scores representing better health-related quality of life. IWQOL-kids data at week 82 was not collected, thus could not be evaluated. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  27. Change in BMI SDS (%)

    Relative change in BMI SDS was evaluated from baseline (week 0) to weeks 30 and 56. Results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.

    Time frame: (Week 0, week 30); (Week 0, week 56)

  28. Change in Nutritional Compliance

    This outcome measure presents "nutritional compliance results" recorded at baseline (week 0), week 30 and week 56. Nutritional compliance was recorded on a 0 to 10 numeric rating scale, with higher scores representing better compliance. Week 30 and 56 results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.

    Time frame: Week 0, week 30 and week 56

  29. Number of Treatment Emergent Adverse Events

    A treatment emergent adverse event (TEAE) was defined as an event that occurred in the "on-treatment" period. 'On-treatment' period: Events with onset date between the first day of trial product administration and any of the following date, whichever came first: 1) 14 days after the last day on trial product, or 2) follow-up visit (week 58) for participants who discontinued trial product, or 3) last study visit (participants withdrawn without follow-up visit).

    Time frame: Week 0-56 + 14 days

  30. Number of Treatment Emergent Hypoglycaemic Episodes (ADA/ISPAD Classification)

    A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia episodes were recorded as per international society for pediatric and adolescent diabetes (ISPAD) definition. And the following presented hypoglycaemia episodes were recorded as per American Diabetes Association (ADA) definition: asymptomatic hypoglycaemia, documented symptomatic hypoglycaemia, pseudo-hypoglycaemia and probable symptomatic hypoglycaemia.

    Time frame: Week 0-56 + 14 days

  31. Number of Treatment Emergent Hypoglycaemic Episodes (Novo Nordisk/ISPAD Classification)

    Severe hypoglycaemia episodes were recorded as per the ISPAD definition. And the following presented hypoglycaemia episodes were recorded as per Novo Nordisk definition: Symptomatic BG-confirmed: An episode that is blood glucose (BG) confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Asymptomatic BG-confirmed: An episode that is BG-confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. 4) Severe or BG-confirmed symptomatic: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. 5) BG-confirmed: An episode that is BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. 6) Severe or BG-confirmed: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia.

    Time frame: Week 0-56 + 14 days

  32. Occurrence of Anti-liraglutide Antibodies

    This outcome measure is only applicable for the liraglutide 3.0 mg treatment arm. Number of participants who measured with anti-liraglutide binding antibodies at weeks 0, 30, 56, 58, 70 and 82 are presented.

    Time frame: Weeks 0, 30, 56, 58, 70 and 82

  33. Change in Pulse

    Change in pulse was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  34. Change in ECG

    This outcome measure presents number of subjects with electrocardiogram findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" recorded at baseline (week -14), week 30 and week 56. These findings were categorised by the investigator. Electrocardiogram (ECG) data at week 82 was not collected, thus could not be evaluated. Week 30 and 56 results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.

    Time frame: Week -14, week 30, week 56 and week 82

  35. Change in Haematology: Haemoglobin

    Change in haemoglobin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  36. Change in Haematology: Haematocrit

    Change in haematocrit was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  37. Change in Haematology: Thrombocytes, Leucocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes and Monocytes

    Change in haematological parameters, "thrombocytes, leucocytes, eosinophils, neutrophils, basophils, lymphocytes and monocytes" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  38. Change in Haematology: Erythrocytes

    Change in erythrocytes was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  39. Change in Biochemistry: Creatinine and Bilirubin (Total)

    Change in creatinine and bilirubin (total) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  40. Change in Biochemistry: Creatinine Kinase, Amylase, Lipase, ALT, AST and ALP

    Change in biochemistry parameters, "creatinine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  41. Change in Biochemistry: Urea (BUN), Sodium, Potassium, Calcium Total and Calcium Albumin-corrected

    Change in biochemistry parameters, "urea (blood urea nitrogen \[BUN\]), sodium, potassium, calcium total and calcium (Ca) albumin-corrected" was evaluated from baseline (week \[Wk\] 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  42. Change in Biochemistry: Albumin

    Change in albumin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  43. Change in Biochemistry: CEA

    Change in carcinoembryonic antigen (CEA) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  44. Change in Hormone Level: Calcitonin

    Change in calcitonin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  45. Change in Hormone Level: TSH and Prolactin

    Change in hormone levels, "thyroid stimulating hormone (TSH) and prolactin" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  46. Change in Hormone Level: Free T4 and ACTH

    Change in hormone levels, "thyroxine (T4) and adrenocorticotropic hormone (ACTH)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  47. Change in Hormone Level: IGF-1 and Cortisol

    Change in hormone levels, "insulin-like growth factor-1 (IGF-1) and cortisol" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  48. Change in Hormone Level: DHEAS

    Change in dehydroepiandrosterone sulfate (DHEAS) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  49. Change in Hormone Level: LH and FSH

    Change in hormone levels, "luteinising hormone (LH) and follicle stimulating hormone (FSH)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  50. Change in Hormone Level: Estradiol (Females)

    Change in estradiol (only for female) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  51. Change in Hormone Level: Testosterone (Males)

    This outcome measure presents "testosterone (only for males) results" for baseline (week 0), week 30, week 56 and week 82. ADVIA Centaur Testosterone (TSTO) assay was used for the evaluation of testosterone hormone. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: Week 0, week 30, week 56 and week 82

  52. Change in NTX1

    Change in type I collagen N-telopeptide (NTX1) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are presented in "nmol bone collagen equivalents (BCE)/L". Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  53. Change in CTX1

    Change in type I collagen C-telopeptide (CTX1) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  54. Change in P1NP

    Change in procollagen 1 N-terminal propeptide (P1NP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  55. Change in Alkaline Phosphatase (Bone)

    Change in alkaline phosphatase (bone specific) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  56. Change in Pubertal Status

    This outcome measure presents "pubertal status results" which is based on Tanner staging (Tanner stage 2-5), recorded at baseline (week 0), week 30, week 56 and week 82. Results are presented for the following categories: 1) For female: breast development and pubic hair development (by Tanner staging). 2) For male: penis development and pubic hair development (by Tanner staging). Each category shows number of participants in stages 2 to 5, where stage 2 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult". Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  57. Change in Physical Examination

    This outcome measure presents number of subjects with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 30, week 56 and week 82. These findings were categorised by the investigator. Results include examination of: "general appearance"; "head, ears, eyes, nose, throat, neck"; "respiratory system"; "cardiovascular system (CVS)"; "gastrointestinal (GI) system including mouth"; "musculoskeletal system"; "central nervous system (CNS) and peripheral nervous system (PNS)"; "skin"; "thyroid gland" and "lymph node palpation". Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: Week 0, week 30, week 56 and week 82

  58. Change in Height SDS

    Change in height standard deviation score (SDS) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  59. Change in C-SSRS

    This outcome measure presents number of subjects with "suicidal ideation or suicidal behaviour on the Columbia Suicidality Severity Rating Scale (C-SSRS)" assessed at baseline (week 0), week 30, week 56 and week 82. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

  60. Change in PHQ-9

    Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

    Time frame: (Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

08

Results

Posted Apr 27, 2020

Participant flow

This trial was conducted at 32 sites in 5 countries: Belgium (6 sites), Sweden (4 sites), Russia (8 sites), Mexico (2 sites) and the United States of America (USA - 12 sites). Additionally, 1 site in the USA was approved by the independent review board, but did not randomise any participant.

Participant flow — Overall Study
MilestoneLiraglutide 3.0 mgPlacebo
Started125126
Full analysis set125126
Safety analysis set125126
Completed112103
Not completed1323
Withdrew: Lost to follow-up36
Withdrew: Withdrawal by subject515
Withdrew: Withdrawal by parent/guardian21
Withdrew: Other31

Outcome measures

PrimaryChange in BMI SDS (Week 0, Week 56)

Change from baseline (week 0) in BMI SDS was evaluated at week 56. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the world health organisation (WHO) Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation. Results are based on both participants who completed the week 0-56 trial period and participants who prematurely discontinued the trial product but attended the follow-up visit at 56.

Time frame:
Week 0, week 56
Reported as:
Mean · SDS score
Change in BMI SDS (Week 0, Week 56)
SDS scoreLiraglutide 3.0 mgPlacebo
Change in BMI SDS (Week 0, Week 56)-0.25 ± 0.51-0.02 ± 0.54
Statistical analysis
  • Liraglutide 3.0 mg vs Placebo · ANCOVA · p = 0.0022 · Treatment difference: -0.22 · 95% CI -0.37 to -0.08Liraglutide 3.0 mg - Placebo
SecondaryPercent of Subjects Achieving ≥5% Reduction in Baseline BMI

Participants achieving more than or equal to 5% reduction in their baseline (week 0) BMI was evaluated at weeks 30, 56 and 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

Time frame:
Weeks 30, 56 and 82
Reported as:
Number · Percentage of participants
Percent of Subjects Achieving ≥5% Reduction in Baseline BMI
Percentage of participantsLiraglutide 3.0 mgPlacebo
Week 30 (Yes)46.214.7
Week 30 (No)53.885.3
Week 56 (Yes)45.119.0
Week 56 (No)54.981.0
Week 82 (Yes)29.518.6
Week 82 (No)70.581.4
SecondaryPercent of Subjects Achieving ≥10% Reduction in Baseline BMI

Participants achieving more than or equal to 10% reduction in their baseline (week 0) BMI was evaluated at weeks 30, 56 and 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

Time frame:
Weeks 30, 56 and 82
Reported as:
Number · Percentage of participants
Percent of Subjects Achieving ≥10% Reduction in Baseline BMI
Percentage of participantsLiraglutide 3.0 mgPlacebo
Week 30 (Yes)24.45.2
Week 30 (No)75.694.8
Week 56 (Yes)29.28.6
Week 56 (No)70.891.4
Week 82 (Yes)18.810.8
Week 82 (No)81.389.2
SecondaryChange in BMI SDS ((Week 0, Week 30); (Week 0, Week 82); (Week 56, Week 82))

Change in BMI SDS was evaluated from baseline (week 0) to weeks 30 and 82, and from week 56 to week 82. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a Z (SDS) score was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation. Results are based on both participants who completed the trial period, week 0-30 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30 or 82, respectively.

Time frame:
(Week 0, week 30); (Week 0, week 82); (Week 56, week 82)
Reported as:
Mean · SDS score
Change in BMI SDS ((Week 0, Week 30); (Week 0, Week 82); (Week 56, Week 82))
SDS scoreLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-0.26 ± 0.34-0.04 ± 0.33
Change from week 0 to week 82-0.06 ± 0.530.07 ± 0.66
Change from week 56 to week 820.22 ± 0.280.08 ± 0.27
SecondaryChange in BMI

Change in BMI was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · kg/m^2
Change in BMI
kg/m^2Liraglutide 3.0 mgPlacebo
Change from week 0 to week 30-1.8 ± 2.1-0.2 ± 2.2
Change from week 0 to week 56-1.6 ± 3.10.1 ± 3.4
Change from week 56 to week 821.5 ± 1.70.7 ± 1.7
SecondaryChange in Body Weight (kg)

Change in body weight (kg) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · kg
Change in Body Weight (kg)
kgLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-3.9 ± 6.10.4 ± 6.6
Change from week 0 to week 56-2.7 ± 9.12.1 ± 10.2
Change from week 56 to week 824.7 ± 4.62.4 ± 4.9
SecondaryChange in Body Weight (%)

Relative change in body weight (kg) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · Percentage change
Change in Body Weight (%)
Percentage changeLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-4.3 ± 6.50.4 ± 6.2
Change from week 0 to week 56-3.2 ± 9.42.2 ± 9.5
Change from week 56 to week 825.3 ± 5.72.3 ± 4.9
SecondaryChange in Body Weight (lb)

Body weight was not analysed in pounds (lb). It was analysed for standard unit, 'kg' only.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)

No measurements were reported for this outcome.

SecondaryChange in Waist Circumference

Change in waist circumference was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · cm
Change in Waist Circumference
cmLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-4.63 ± 6.24-2.01 ± 5.94
Change from week 0 to week 56-5.12 ± 7.87-1.51 ± 8.20
Change from week 56 to week 823.58 ± 4.301.24 ± 5.60
SecondaryChange in Waist-to-hip Circumference Ratio

Change in waist-to-hip circumference ratio was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · Ratio
Change in Waist-to-hip Circumference Ratio
RatioLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-0.015 ± 0.042-0.018 ± 0.042
Change from week 0 to week 56-0.022 ± 0.053-0.023 ± 0.051
Change from week 56 to week 820.010 ± 0.0310.003 ± 0.049
SecondaryChange in hsCRP

Change in high sensitivity C reactive protein (hsCRP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · mg/L
Change in hsCRP
mg/LLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-0.22 ± 5.04-0.56 ± 4.68
Change from week 0 to week 56-0.25 ± 4.54-0.14 ± 3.44
Change from week 56 to week 821.51 ± 7.611.00 ± 4.22
SecondaryChange in Fasting Lipid: Total Cholesterol (Ratio to Baseline)

Change in total cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Fasting Lipid: Total Cholesterol (Ratio to Baseline)
Ratio of total cholesterolLiraglutide 3.0 mgPlacebo
Change from week 0 to week 301.00 ± 12.80.98 ± 13.0
Change from week 0 to week 561.00 ± 14.21.00 ± 13.0
Change from week 56 to week 821.02 ± 14.71.02 ± 14.9
SecondaryChange in Fasting Lipid: LDL-cholesterol (Ratio to Baseline)

Change in low density lipoprotein (LDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of LDL-cholesterol
Change in Fasting Lipid: LDL-cholesterol (Ratio to Baseline)
Ratio of LDL-cholesterolLiraglutide 3.0 mgPlacebo
Change from week 0 to week 301.00 ± 19.81.00 ± 26.1
Change from week 0 to week 560.99 ± 21.81.02 ± 23.6
Change from week 56 to week 821.03 ± 22.51.04 ± 20.6
SecondaryChange in Fasting Lipid: HDL-cholesterol (Ratio to Baseline)

Change in high density lipoprotein (HDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of HDL-cholesterol
Change in Fasting Lipid: HDL-cholesterol (Ratio to Baseline)
Ratio of HDL-cholesterolLiraglutide 3.0 mgPlacebo
Change from week 0 to week 301.04 ± 15.31.01 ± 20.5
Change from week 0 to week 561.04 ± 17.41.02 ± 18.9
Change from week 56 to week 820.99 ± 15.81.00 ± 15.2
SecondaryChange in Fasting Lipid: Non-HDL Cholesterol (Ratio to Baseline)

Change in non-HDL cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of non-HDL cholesterol
Change in Fasting Lipid: Non-HDL Cholesterol (Ratio to Baseline)
Ratio of non-HDL cholesterolLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.98 ± 16.80.97 ± 18.0
Change from week 0 to week 560.98 ± 18.40.99 ± 16.7
Change from week 56 to week 821.03 ± 19.81.02 ± 18.6
SecondaryChange in Fasting Lipid: VLDL Cholesterol (Ratio to Baseline)

Change in very low density lipoprotein (VLDL) cholesterol from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of VLDL cholesterol
Change in Fasting Lipid: VLDL Cholesterol (Ratio to Baseline)
Ratio of VLDL cholesterolLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.91 ± 36.80.90 ± 42.7
Change from week 0 to week 560.92 ± 43.70.93 ± 34.6
Change from week 56 to week 821.04 ± 51.00.97 ± 34.1
SecondaryChange in Fasting Lipid: Triglycerides (Ratio to Baseline)

Change in triglycerides from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of triglycerides
Change in Fasting Lipid: Triglycerides (Ratio to Baseline)
Ratio of triglyceridesLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.91 ± 36.90.91 ± 42.9
Change from week 0 to week 560.92 ± 43.20.93 ± 34.4
Change from week 56 to week 821.04 ± 50.40.97 ± 34.0
SecondaryChange in Fasting Lipid: FFA (Ratio to Baseline)

Change in free fatty acids (FFA) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of FFA
Change in Fasting Lipid: FFA (Ratio to Baseline)
Ratio of FFALiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.96 ± 57.70.83 ± 56.4
Change from week 0 to week 561.00 ± 48.90.95 ± 50.8
Change from week 56 to week 820.99 ± 55.20.94 ± 38.0
SecondaryChange in Systolic and Diastolic Blood Pressure

Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · mmHg
Change in Systolic and Diastolic Blood Pressure
mmHgLiraglutide 3.0 mgPlacebo
SBP: Change from week 0 to week 30-2 ± 9-1 ± 10
SBP: Change from week 0 to week 56-2 ± 101 ± 10
SBP: Change from week 56 to week 822 ± 91 ± 10
DBP: Change from week 0 to week 30-0 ± 8-1 ± 10
DBP: Change from week 0 to week 561 ± 9-1 ± 9
DBP: Change from week 56 to week 822 ± 82 ± 7
SecondaryChange in HbA1c

Change in glycosylated haemoglobin (HbA1c) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · Percentage of HbA1c
Change in HbA1c
Percentage of HbA1cLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-0.1 ± 0.3-0.0 ± 0.3
Change from week 0 to week 56-0.1 ± 0.3-0.0 ± 0.2
Change from week 56 to week 820.1 ± 0.20.1 ± 0.3
SecondaryChange in FPG

Change in fasting plasma glucose (FPG) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed treatment for the corresponding treatment period (week 0-30, week 0-56 or week 0-82).

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · mmol/L
Change in FPG
mmol/LLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-0.2 ± 0.4-0.0 ± 0.5
Change from week 0 to week 56-0.1 ± 0.5-0.0 ± 0.6
Change from week 56 to week 820.1 ± 0.60.1 ± 0.5
SecondaryChange in Fasting Insulin (Ratio to Baseline)

Change in fasting insulin from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of fasting insulin
Change in Fasting Insulin (Ratio to Baseline)
Ratio of fasting insulinLiraglutide 3.0 mgPlacebo
Change from week 0 to week 301.13 ± 70.91.14 ± 53.7
Change from week 0 to week 561.06 ± 69.41.10 ± 73.8
Change from week 56 to week 821.00 ± 60.91.08 ± 55.2
SecondaryChange in Fasting C-peptide (Ratio to Baseline)

Change in fasting C-peptide from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of fasting C-peptide
Change in Fasting C-peptide (Ratio to Baseline)
Ratio of fasting C-peptideLiraglutide 3.0 mgPlacebo
Change from week 0 to week 301.12 ± 42.61.04 ± 35.1
Change from week 0 to week 560.98 ± 44.90.97 ± 47.4
Change from week 56 to week 820.92 ± 43.60.94 ± 32.9
SecondaryChange in Glycaemic Category

Number of participants in glycaemic categories, "normoglycaemia, pre-diabetes and type 2 diabetes (T2DM)" at baseline (weeks -2), and weeks 30, 56 and 82 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \<5.6 mmol/L (\<100 mg/dL) and/or HbA1c \<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes (T2DM): FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
Week -2, week 30, week 56 and week 82
Reported as:
Count of participants · Participants
Change in Glycaemic Category
ParticipantsLiraglutide 3.0 mgPlacebo
Week -2 — Normoglycaemia9393
Week -2 — Pre-diabetes3132
Week -2 — Type 2 diabetes11
Week 30 — Normoglycaemia9586
Week 30 — Pre-diabetes1929
Week 30 — Type 2 diabetes21
Week 56 — Normoglycaemia8675
Week 56 — Pre-diabetes1724
Week 56 — Type 2 diabetes22
Week 82 — Normoglycaemia7965
Week 82 — Pre-diabetes2030
Week 82 — Type 2 diabetes14
SecondaryChange in HOMA-B (Ratio to Baseline)

Change in homeostasis model assessment of beta-cell function (HOMA-B) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\[mU/L\]/(FPG\[mmol/L\]-3.5). Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of HOMA-B
Change in HOMA-B (Ratio to Baseline)
Ratio of HOMA-BLiraglutide 3.0 mgPlacebo
Change from week 0 to week 301.32 ± 70.81.17 ± 59.5
Change from week 0 to week 561.13 ± 67.01.11 ± 58.0
Change from week 56 to week 820.92 ± 65.91.02 ± 50.2
SecondaryChange in HOMA-IR (Ratio to Baseline)

Change in homeostasis model assessment of insulin resistance (HOMA-IR) from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82 are presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting insulin \[mU/L\] x FPG \[mmol/L\]/ 22.5. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Geometric mean · Ratio of HOMA-IR
Change in HOMA-IR (Ratio to Baseline)
Ratio of HOMA-IRLiraglutide 3.0 mgPlacebo
Change from week 0 to week 301.08 ± 75.21.14 ± 55.6
Change from week 0 to week 561.04 ± 75.31.09 ± 80.0
Change from week 56 to week 821.03 ± 64.21.11 ± 60.5
SecondaryChange in IWQOL-Kids

Change in Impact of Weight on Quality of Life-Kids (IWQOL-Kids) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. The IWQOL-Kids is a 27-item measure of weight-related quality of life. There are four domain scores (Physical Comfort, Body Esteem, Social Life and Family Life) and a total score. Scores for all domains and total score range from 0-100, with higher scores representing better health-related quality of life. IWQOL-kids data at week 82 was not collected, thus could not be evaluated. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · Scores on a scale
Change in IWQOL-Kids
Scores on a scaleLiraglutide 3.0 mgPlacebo
Body Esteem: Change from week 0 to week 3010.62 ± 19.886.73 ± 26.87
Body Esteem: Change from week 0 to week 5613.33 ± 19.4713.24 ± 22.72
Family Relation: Change from week 0 to week 302.53 ± 9.66-2.19 ± 17.53
Family Relation: Change from week 0 to week 561.44 ± 14.310.97 ± 5.61
Physical Function: Change from week 0 to week 303.94 ± 15.340.43 ± 22.02
Physical Function: Change from week 0 to week 566.17 ± 15.443.32 ± 16.60
Social Life: Change from week 0 to week 305.32 ± 10.561.76 ± 21.98
Social Life: Change from week 0 to week 565.97 ± 19.486.06 ± 14.04
Total: Change from week 0 to week 306.16 ± 11.042.24 ± 19.69
Total: Change from week 0 to week 567.46 ± 13.706.72 ± 11.62
SecondaryChange in BMI SDS (%)

Relative change in BMI SDS was evaluated from baseline (week 0) to weeks 30 and 56. Results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.

Time frame:
(Week 0, week 30); (Week 0, week 56)
Reported as:
Least squares mean · Percentage change
Change in BMI SDS (%)
Percentage changeLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-8.73 ± 1.05-1.70 ± 1.07
Change from week 0 to week 56-8.32 ± 1.68-0.68 ± 1.74
SecondaryChange in Nutritional Compliance

This outcome measure presents "nutritional compliance results" recorded at baseline (week 0), week 30 and week 56. Nutritional compliance was recorded on a 0 to 10 numeric rating scale, with higher scores representing better compliance. Week 30 and 56 results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.

Time frame:
Week 0, week 30 and week 56
Reported as:
Mean · Score on a scale
Change in Nutritional Compliance
Score on a scaleLiraglutide 3.0 mgPlacebo
Week 07.10 ± 1.747.07 ± 1.69
Week 306.74 ± 2.086.51 ± 1.91
Week 566.87 ± 1.876.45 ± 1.84
SecondaryNumber of Treatment Emergent Adverse Events

A treatment emergent adverse event (TEAE) was defined as an event that occurred in the "on-treatment" period. 'On-treatment' period: Events with onset date between the first day of trial product administration and any of the following date, whichever came first: 1) 14 days after the last day on trial product, or 2) follow-up visit (week 58) for participants who discontinued trial product, or 3) last study visit (participants withdrawn without follow-up visit).

Time frame:
Week 0-56 + 14 days
Reported as:
Number · Events
Number of Treatment Emergent Adverse Events
EventsLiraglutide 3.0 mgPlacebo
Number of Treatment Emergent Adverse Events777627
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes (ADA/ISPAD Classification)

A hypoglycaemic episode was defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia episodes were recorded as per international society for pediatric and adolescent diabetes (ISPAD) definition. And the following presented hypoglycaemia episodes were recorded as per American Diabetes Association (ADA) definition: asymptomatic hypoglycaemia, documented symptomatic hypoglycaemia, pseudo-hypoglycaemia and probable symptomatic hypoglycaemia.

Time frame:
Week 0-56 + 14 days
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes (ADA/ISPAD Classification)
EpisodesLiraglutide 3.0 mgPlacebo
Severe hypoglycaemia00
Asymptomatic hypoglycaemia1217
Documented symptomatic hypoglycaemia316
Probable symptomatic hypoglycaemia12
Pseudo-hypoglycaemia303
Unclassifiable40
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes (Novo Nordisk/ISPAD Classification)

Severe hypoglycaemia episodes were recorded as per the ISPAD definition. And the following presented hypoglycaemia episodes were recorded as per Novo Nordisk definition: Symptomatic BG-confirmed: An episode that is blood glucose (BG) confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Asymptomatic BG-confirmed: An episode that is BG-confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. 4) Severe or BG-confirmed symptomatic: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. 5) BG-confirmed: An episode that is BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. 6) Severe or BG-confirmed: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia.

Time frame:
Week 0-56 + 14 days
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes (Novo Nordisk/ISPAD Classification)
EpisodesLiraglutide 3.0 mgPlacebo
Severe hypoglycaemia00
Asymptomatic BG-confirmed hypoglycaemia11
Symptomatic BG-confirmed hypoglycaemia40
Unclassifiable7327
SecondaryOccurrence of Anti-liraglutide Antibodies

This outcome measure is only applicable for the liraglutide 3.0 mg treatment arm. Number of participants who measured with anti-liraglutide binding antibodies at weeks 0, 30, 56, 58, 70 and 82 are presented.

Time frame:
Weeks 0, 30, 56, 58, 70 and 82
Reported as:
Count of participants · Participants
Occurrence of Anti-liraglutide Antibodies
ParticipantsLiraglutide 3.0 mg
Weeks 00
Weeks 306
Weeks 565
Weeks 5811
Weeks 706
Weeks 822
SecondaryChange in Pulse

Change in pulse was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · Beats/minute
Change in Pulse
Beats/minuteLiraglutide 3.0 mgPlacebo
Change from week 0 to week 304 ± 12-1 ± 12
Change from week 0 to week 564 ± 11-1 ± 12
Change from week 56 to week 82-3 ± 92 ± 11
SecondaryChange in ECG

This outcome measure presents number of subjects with electrocardiogram findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" recorded at baseline (week -14), week 30 and week 56. These findings were categorised by the investigator. Electrocardiogram (ECG) data at week 82 was not collected, thus could not be evaluated. Week 30 and 56 results are based on the participants who completed the corresponding trial period, week 0-30 or week 0-56.

Time frame:
Week -14, week 30, week 56 and week 82
Reported as:
Count of participants · Participants
Change in ECG
ParticipantsLiraglutide 3.0 mgPlacebo
Week -14 — Normal102100
Week -14 — Abnormal, NCS2326
Week -14 — Abnormal, CS00
Week 30 — Normal9795
Week 30 — Abnormal, NCS2021
Week 30 — Abnormal, CS00
Week 56 — Normal8380
Week 56 — Abnormal, NCS2123
Week 56 — Abnormal, CS00
Week 82 — Normal——
Week 82 — Abnormal, NCS——
Week 82 — Abnormal, CS——
SecondaryChange in Haematology: Haemoglobin

Change in haemoglobin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · mmol/L
Change in Haematology: Haemoglobin
mmol/LLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.2 ± 0.50.0 ± 0.4
Change from week 0 to week 560.3 ± 0.60.1 ± 0.6
Change from week 56 to week 82-0.1 ± 0.6-0.0 ± 0.4
SecondaryChange in Haematology: Haematocrit

Change in haematocrit was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · % of red blood cells
Change in Haematology: Haematocrit
% of red blood cellsLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.7 ± 2.30.1 ± 2.4
Change from week 0 to week 561.2 ± 2.70.4 ± 2.8
Change from week 56 to week 82-0.4 ± 2.9-0.4 ± 1.9
SecondaryChange in Haematology: Thrombocytes, Leucocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes and Monocytes

Change in haematological parameters, "thrombocytes, leucocytes, eosinophils, neutrophils, basophils, lymphocytes and monocytes" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · 10^9 cells/L
Change in Haematology: Thrombocytes, Leucocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes and Monocytes
10^9 cells/LLiraglutide 3.0 mgPlacebo
Thrombocytes: Change from week 0 to week 309 ± 3714 ± 38
Thrombocytes: Change from week 0 to week 567 ± 467 ± 39
Thrombocytes: Change from week 56 to week 82-2 ± 313 ± 37
Leucocytes: Change from week 0 to week 300.1 ± 1.6-0.1 ± 2
Leucocytes: Change from week 0 to week 56-0.2 ± 1.6-0.4 ± 1.7
Leucocytes: Change from week 56 to week 820.2 ± 1.50.0 ± 2.0
Eosinophils: Change from week 0 to week 300.03 ± 0.150.04 ± 0.29
Eosinophils: Change from week 0 to week 560.01 ± 0.150.00 ± 0.23
Eosinophils: Change from week 56 to week 82-0.01 ± 0.120.00 ± 0.15
Neutrophils: Change from week 0 to week 300.18 ± 1.33-0.01 ± 1.71
Neutrophils: Change from week 0 to week 56-0.01 ± 1.49-0.13 ± 1.50
Neutrophils: Change from week 56 to week 820.21 ± 1.35-0.00 ± 1.71
Basophils: Change from week 0 to week 300.01 ± 0.030.01 ± 0.03
Basophils: Change from week 0 to week 560.01 ± 0.030.02 ± 0.03
Basophils: Change from week 56 to week 820.00 ± 0.030.00 ± 0.03
Lymphocytes: Change from week 0 to week 30-0.18 ± 0.69-0.14 ± 0.62
Lymphocytes: Change from week 0 to week 56-0.28 ± 0.59-0.27 ± 0.72
Lymphocytes: Change from week 56 to week 82-0.03 ± 0.48-0.00 ± 0.61
Monocytes: Change from week 0 to week 300.04 ± 0.160.00 ± 0.18
Monocytes: Change from week 0 to week 560.06 ± 0.130.01 ± 0.17
Monocytes: Change from week 56 to week 82-0.00 ± 0.150.04 ± 0.18
SecondaryChange in Haematology: Erythrocytes

Change in erythrocytes was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · 10^12 cells/L
Change in Haematology: Erythrocytes
10^12 cells/LLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.0 ± 0.2-0.0 ± 0.3
Change from week 0 to week 56-0.0 ± 0.3-0.1 ± 0.3
Change from week 56 to week 82-0.1 ± 0.30.0 ± 0.2
SecondaryChange in Biochemistry: Creatinine and Bilirubin (Total)

Change in creatinine and bilirubin (total) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · umol/L
Change in Biochemistry: Creatinine and Bilirubin (Total)
umol/LLiraglutide 3.0 mgPlacebo
Creatinine: Change from week 0 to week 301 ± 70 ± 8
Creatinine: Change from week 0 to week 562 ± 74 ± 9
Creatinine: Change from week 56 to week 822 ± 81 ± 10
Bilirubin (total): Change from week 0 to week 301 ± 41 ± 5
Bilirubin (total): Change from week 0 to week 561 ± 41 ± 5
Bilirubin (total): Change from week 56 to week 820 ± 5-0 ± 4
SecondaryChange in Biochemistry: Creatinine Kinase, Amylase, Lipase, ALT, AST and ALP

Change in biochemistry parameters, "creatinine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · U/L
Change in Biochemistry: Creatinine Kinase, Amylase, Lipase, ALT, AST and ALP
U/LLiraglutide 3.0 mgPlacebo
Creatinine kinase: Change from week 0 to week 3013 ± 2510 ± 225
Creatinine kinase: Change from week 0 to week 5632 ± 2280 ± 111
Creatinine kinase: Change from week 56 to week 8228 ± 3214 ± 114
Amylase: Change from week 0 to week 304 ± 123 ± 16
Amylase: Change from week 0 to week 562 ± 10-0 ± 9
Amylase: Change from week 56 to week 82-1 ± 81 ± 11
Lipase: Change from week 0 to week 306 ± 131 ± 19
Lipase: Change from week 0 to week 563 ± 13-2 ± 5
Lipase: Change from week 56 to week 82-4 ± 9-0 ± 5
ALT: Change from week 0 to week 30-2 ± 15-1 ± 15
ALT: Change from week 0 to week 56-2 ± 16-0 ± 23
ALT: Change from week 56 to week 821 ± 122 ± 20
AST: Change from week 0 to week 30-1 ± 8-1 ± 11
AST: Change from week 0 to week 56-1 ± 8-1 ± 11
AST: Change from week 56 to week 821 ± 121 ± 11
ALP: Change from week 0 to week 30-16 ± 25-8 ± 66
ALP: Change from week 0 to week 56-23 ± 36-19 ± 53
ALP: Change from week 56 to week 82-2 ± 22-10 ± 24
SecondaryChange in Biochemistry: Urea (BUN), Sodium, Potassium, Calcium Total and Calcium Albumin-corrected

Change in biochemistry parameters, "urea (blood urea nitrogen \[BUN\]), sodium, potassium, calcium total and calcium (Ca) albumin-corrected" was evaluated from baseline (week \[Wk\] 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · mmol/L
Change in Biochemistry: Urea (BUN), Sodium, Potassium, Calcium Total and Calcium Albumin-corrected
mmol/LLiraglutide 3.0 mgPlacebo
Urea (BUN): Change from week 0 to week 30-0.06 ± 1.070.00 ± 1.14
Urea (BUN): Change from week 0 to week 56-0.26 ± 1.01-0.05 ± 1.19
Urea (BUN): Change from week 56 to week 820.23 ± 1.110.00 ± 1.07
Sodium: Change from week 0 to week 300 ± 20 ± 2
Sodium: Change from week 0 to week 560 ± 20 ± 3
Sodium: Change from week 56 to week 82-1 ± 3-1 ± 3
Potassium: Change from week 0 to week 30-0.0 ± 0.40.0 ± 0.3
Potassium: Change from week 0 to week 56-0.1 ± 0.4-0.0 ± 0.3
Potassium: Change from week 56 to week 820.0 ± 0.3-0.0 ± 0.4
Calcium total: Change from week 0 to week 30-0.01 ± 0.09-0.03 ± 0.09
Calcium total: Change from week 0 to week 56-0.04 ± 0.10-0.04 ± 0.09
Calcium total: Change from week 56 to week 82-0.00 ± 0.09-0.01 ± 0.09
Ca albumin-corrected:Change from week 0 to week 30-0.04 ± 0.09-0.03 ± 0.09
Ca albumin-corrected:Change from week 0 to week 56-0.07 ± 0.10-0.07 ± 0.08
Ca albumin-corrected: Change from Wk 56 to Wk 820.01 ± 0.07-0.00 ± 0.09
SecondaryChange in Biochemistry: Albumin

Change in albumin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · g/dL
Change in Biochemistry: Albumin
g/dLLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.1 ± 0.20.0 ± 0.3
Change from week 0 to week 560.1 ± 0.30.1 ± 0.3
Change from week 56 to week 82-0.0 ± 0.2-0.0 ± 0.3
SecondaryChange in Biochemistry: CEA

Change in carcinoembryonic antigen (CEA) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · ng/mL
Change in Biochemistry: CEA
ng/mLLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-0.0 ± 0.3-0.1 ± 0.6
Change from week 0 to week 560.0 ± 0.4-0.0 ± 0.6
Change from week 56 to week 820.0 ± 0.40.0 ± 0.3
SecondaryChange in Hormone Level: Calcitonin

Change in calcitonin was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · ng/L
Change in Hormone Level: Calcitonin
ng/LLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.1 ± 0.80.1 ± 0.7
Change from week 0 to week 560.0 ± 0.7-0.0 ± 0.8
Change from week 56 to week 82-0.1 ± 0.60.2 ± 1.5
SecondaryChange in Hormone Level: TSH and Prolactin

Change in hormone levels, "thyroid stimulating hormone (TSH) and prolactin" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · mIU/L
Change in Hormone Level: TSH and Prolactin
mIU/LLiraglutide 3.0 mgPlacebo
TSH: Change from week 0 to week 30-0.35 ± 1.37-0.08 ± 1.17
TSH: Change from week 0 to week 56-0.42 ± 1.36-0.14 ± 1.28
TSH: Change from week 56 to week 820.38 ± 1.910.13 ± 1.57
Prolactin: Change from week 0 to week 3023 ± 165-47 ± 452
Prolactin: Change from week 0 to week 5663 ± 312-63 ± 684
Prolactin: Change from week 56 to week 82-29 ± 39613 ± 98
SecondaryChange in Hormone Level: Free T4 and ACTH

Change in hormone levels, "thyroxine (T4) and adrenocorticotropic hormone (ACTH)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · pmol/L
Change in Hormone Level: Free T4 and ACTH
pmol/LLiraglutide 3.0 mgPlacebo
T4: Change from week 0 to week 300.6 ± 1.90.8 ± 2.1
T4: Change from week 0 to week 560.3 ± 1.80.6 ± 2.1
T4: Change from week 56 to week 820.0 ± 1.60.2 ± 2.3
ACTH: Change from week 0 to week 300.4 ± 4.40.5 ± 3.9
ACTH: Change from week 0 to week 560.6 ± 4.90.6 ± 3.8
ACTH: Change from week 56 to week 82-0.8 ± 4.7-0.4 ± 2.9
SecondaryChange in Hormone Level: IGF-1 and Cortisol

Change in hormone levels, "insulin-like growth factor-1 (IGF-1) and cortisol" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · ng/mL
Change in Hormone Level: IGF-1 and Cortisol
ng/mLLiraglutide 3.0 mgPlacebo
IGF-1: Change from week 0 to week 3010.61 ± 89.833.79 ± 101.12
IGF-1: Change from week 0 to week 56-4.60 ± 84.513.69 ± 111.63
IGF-1: Change from week 56 to week 82-14.60 ± 80.82-16.35 ± 65.89
Cortisol: Change from week 0 to week 306.9 ± 66.98.6 ± 60.1
Cortisol: Change from week 0 to week 565.1 ± 65.28.5 ± 57.9
Cortisol: Change from week 56 to week 820.6 ± 66.610.4 ± 61.2
SecondaryChange in Hormone Level: DHEAS

Change in dehydroepiandrosterone sulfate (DHEAS) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · umol/L
Change in Hormone Level: DHEAS
umol/LLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.94 ± 1.660.57 ± 1.78
Change from week 0 to week 560.95 ± 1.910.89 ± 2.05
Change from week 56 to week 82-0.08 ± 2.11-0.05 ± 1.27
SecondaryChange in Hormone Level: LH and FSH

Change in hormone levels, "luteinising hormone (LH) and follicle stimulating hormone (FSH)" was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · IU/L
Change in Hormone Level: LH and FSH
IU/LLiraglutide 3.0 mgPlacebo
LH: Change from week 0 to week 300.4 ± 9.10.7 ± 7.9
LH: Change from week 0 to week 560.2 ± 9.10.6 ± 6.6
LH: Change from week 56 to week 820.4 ± 8.7-0.5 ± 8.0
FSH: Change from week 0 to week 300.2 ± 2.6-0.2 ± 2.7
FSH: Change from week 0 to week 560.6 ± 4.00.1 ± 2.5
FSH: Change from week 56 to week 82-0.1 ± 3.6-0.1 ± 3.1
SecondaryChange in Hormone Level: Estradiol (Females)

Change in estradiol (only for female) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · pg/mL
Change in Hormone Level: Estradiol (Females)
pg/mLLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-5.0 ± 81.020.2 ± 67.6
Change from week 0 to week 5611.6 ± 94.414.1 ± 63.6
Change from week 56 to week 82-2.3 ± 89.1-1.7 ± 65.3
SecondaryChange in Hormone Level: Testosterone (Males)

This outcome measure presents "testosterone (only for males) results" for baseline (week 0), week 30, week 56 and week 82. ADVIA Centaur Testosterone (TSTO) assay was used for the evaluation of testosterone hormone. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
Week 0, week 30, week 56 and week 82
Reported as:
Mean · nmol/L
Change in Hormone Level: Testosterone (Males)
nmol/LLiraglutide 3.0 mgPlacebo
Week 08.13 ± 3.458.06 ± 3.66
Week 3010.00 ± 4.029.33 ± 5.27
Week 5610.55 ± 4.149.51 ± 3.31
Week 8211.36 ± 5.276.16 ± 3.27
SecondaryChange in NTX1

Change in type I collagen N-telopeptide (NTX1) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are presented in "nmol bone collagen equivalents (BCE)/L". Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · nmol BCE/L
Change in NTX1
nmol BCE/LLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-2.4 ± 10.4-3.2 ± 12.0
Change from week 0 to week 56-3.7 ± 14.1-2.9 ± 15.1
Change from week 56 to week 82-2.8 ± 12.8-4.6 ± 10.0
SecondaryChange in CTX1

Change in type I collagen C-telopeptide (CTX1) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · pg/mL
Change in CTX1
pg/mLLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-7 ± 358-84 ± 404
Change from week 0 to week 56-36 ± 353-97 ± 473
Change from week 56 to week 82-107 ± 359-162 ± 318
SecondaryChange in P1NP

Change in procollagen 1 N-terminal propeptide (P1NP) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · ng/mL
Change in P1NP
ng/mLLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-35 ± 124-30 ± 184
Change from week 0 to week 56-55 ± 151-63 ± 192
Change from week 56 to week 82-30 ± 107-47 ± 84
SecondaryChange in Alkaline Phosphatase (Bone)

Change in alkaline phosphatase (bone specific) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · U/L
Change in Alkaline Phosphatase (Bone)
U/LLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-15 ± 16-12 ± 26
Change from week 0 to week 56-17 ± 18-17 ± 30
Change from week 56 to week 82-1 ± 11-4 ± 12
SecondaryChange in Pubertal Status

This outcome measure presents "pubertal status results" which is based on Tanner staging (Tanner stage 2-5), recorded at baseline (week 0), week 30, week 56 and week 82. Results are presented for the following categories: 1) For female: breast development and pubic hair development (by Tanner staging). 2) For male: penis development and pubic hair development (by Tanner staging). Each category shows number of participants in stages 2 to 5, where stage 2 represents "early pubertal development" and stage 5 represents "pubertal development equivalent to that of an adult". Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Count of participants · Participants
Change in Pubertal Status
ParticipantsLiraglutide 3.0 mgPlacebo
Week 0: Breast development (for female) — Stage 221
Week 0: Breast development (for female) — Stage 368
Week 0: Breast development (for female) — Stage 42330
Week 0: Breast development (for female) — Stage 54039
Week 30: Breast development (for female) — Stage 210
Week 30: Breast development (for female) — Stage 346
Week 30: Breast development (for female) — Stage 42225
Week 30: Breast development (for female) — Stage 53943
Week 56: Breast development (for female) — Stage 200
Week 56: Breast development (for female) — Stage 322
Week 56: Breast development (for female) — Stage 41420
Week 56: Breast development (for female) — Stage 54141
Week 82: Breast development (for female) — Stage 200
Week 82: Breast development (for female) — Stage 302
Week 82: Breast development (for female) — Stage 4713
Week 82: Breast development (for female) — Stage 54646
Week 0: Pubic hair development (for female) — Stage 223
Week 0: Pubic hair development (for female) — Stage 365
Week 0: Pubic hair development (for female) — Stage 42226
Week 0: Pubic hair development (for female) — Stage 54144
Week 30: Pubic hair development (for female) — Stage 210
Week 30: Pubic hair development (for female) — Stage 344
Week 30: Pubic hair development (for female) — Stage 42025
Week 30: Pubic hair development (for female) — Stage 54145
Week 56: Pubic hair development (for female) — Stage 210
Week 56: Pubic hair development (for female) — Stage 322
Week 56: Pubic hair development (for female) — Stage 41321
Week 56: Pubic hair development (for female) — Stage 54140
Week 82: Pubic hair development (for female) — Stage 200
Week 82: Pubic hair development (for female) — Stage 312
Week 82: Pubic hair development (for female) — Stage 4714
Week 82: Pubic hair development (for female) — Stage 54545
Week 0: penis development (male) — Stage 247
Week 0: penis development (male) — Stage 3118
Week 0: penis development (male) — Stage 41614
Week 0: penis development (male) — Stage 52319
Week 30: penis development (male) — Stage 212
Week 30: penis development (male) — Stage 3117
Week 30: penis development (male) — Stage 41411
Week 30: penis development (male) — Stage 52525
Week 56: penis development (male) — Stage 210
Week 56: penis development (male) — Stage 366
Week 56: penis development (male) — Stage 4156
Week 56: penis development (male) — Stage 52629
Week 82: penis development (male) — Stage 200
Week 82: penis development (male) — Stage 333
Week 82: penis development (male) — Stage 4116
Week 82: penis development (male) — Stage 53129
Week 0: Pubic hair development (male) — Stage 269
Week 0: Pubic hair development (male) — Stage 385
Week 0: Pubic hair development (male) — Stage 41913
Week 0: Pubic hair development (male) — Stage 52121
Week 30: Pubic hair development (male) — Stage 213
Week 30: Pubic hair development (male) — Stage 3107
Week 30: Pubic hair development (male) — Stage 4159
Week 30: Pubic hair development (male) — Stage 52426
Week 56: Pubic hair development (male) — Stage 210
Week 56: Pubic hair development (male) — Stage 376
Week 56: Pubic hair development (male) — Stage 4157
Week 56: Pubic hair development (male) — Stage 52428
Week 82: Pubic hair development (male) — Stage 200
Week 82: Pubic hair development (male) — Stage 332
Week 82: Pubic hair development (male) — Stage 4108
Week 82: Pubic hair development (male) — Stage 53028
SecondaryChange in Physical Examination

This outcome measure presents number of subjects with physical examination findings, "normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)" at baseline (week 0), week 30, week 56 and week 82. These findings were categorised by the investigator. Results include examination of: "general appearance"; "head, ears, eyes, nose, throat, neck"; "respiratory system"; "cardiovascular system (CVS)"; "gastrointestinal (GI) system including mouth"; "musculoskeletal system"; "central nervous system (CNS) and peripheral nervous system (PNS)"; "skin"; "thyroid gland" and "lymph node palpation". Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
Week 0, week 30, week 56 and week 82
Reported as:
Count of participants · Participants
Change in Physical Examination
ParticipantsLiraglutide 3.0 mgPlacebo
General Appearance: Week 0 — Normal93101
General Appearance: Week 0 — Abnormal, NCS3023
General Appearance: Week 0 — Abnormal, CS22
General Appearance: Week 30 — Normal9495
General Appearance: Week 30 — Abnormal, NCS2120
General Appearance: Week 30 — Abnormal, CS11
General Appearance: Week 56 — Normal8485
General Appearance: Week 56 — Abnormal, NCS1816
General Appearance: Week 56 — Abnormal, CS21
General Appearance: Week 82 — Normal8081
General Appearance: Week 82 — Abnormal, NCS1817
General Appearance: Week 82 — Abnormal, CS11
Head, ears, eyes, nose, throat, neck: Week 0 — Normal120116
Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, NCS510
Head, ears, eyes, nose, throat, neck: Week 0 — Abnormal, CS00
Head, ears, eyes, nose, throat, neck: Week 30 — Normal114107
Head, ears, eyes, nose, throat, neck: Week 30 — Abnormal, NCS29
Head, ears, eyes, nose, throat, neck: Week 30 — Abnormal, CS00
Head, ears, eyes, nose, throat, neck: Week 56 — Normal10198
Head, ears, eyes, nose, throat, neck: Week 56 — Abnormal, NCS34
Head, ears, eyes, nose, throat, neck: Week 56 — Abnormal, CS00
Head, ears, eyes, nose, throat, neck: Week 82 — Normal9894
Head, ears, eyes, nose, throat, neck: Week 82 — Abnormal, NCS15
Head, ears, eyes, nose, throat, neck: Week 82 — Abnormal, CS00
Respiratory system: Week 0 — Normal125123
Respiratory system: Week 0 — Abnormal, NCS03
Respiratory system: Week 0 — Abnormal, CS00
Respiratory system: Week 30 — Normal116115
Respiratory system: Week 30 — Abnormal, NCS01
Respiratory system: Week 30 — Abnormal, CS00
Respiratory system: Week 56 — Normal104101
Respiratory system: Week 56 — Abnormal, NCS01
Respiratory system: Week 56 — Abnormal, CS00
Respiratory system: Week 82 — Normal9996
Respiratory system: Week 82 — Abnormal, NCS03
Respiratory system: Week 82 — Abnormal, CS00
Cardiovascular system: Week 0 — Normal124125
Cardiovascular system: Week 0 — Abnormal, NCS11
Cardiovascular system: Week 0 — Abnormal, CS00
Cardiovascular system: Week 30 — Normal115112
Cardiovascular system: Week 30 — Abnormal, NCS14
Cardiovascular system: Week 30 — Abnormal, CS00
Cardiovascular system: Week 56 — Normal102100
Cardiovascular system: Week 56 — Abnormal, NCS22
Cardiovascular system: Week 56 — Abnormal, CS00
Cardiovascular system: Week 82 — Normal9798
Cardiovascular system: Week 82 — Abnormal, NCS21
Cardiovascular system: Week 82 — Abnormal, CS00
GI system including mouth: Week 0 — Normal119119
GI system including mouth: Week 0 — Abnormal, NCS56
GI system including mouth: Week 0 — Abnormal, CS11
GI system including mouth: Week 30 — Normal111109
GI system including mouth: Week 30 — Abnormal, NCS56
GI system including mouth: Week 30 — Abnormal, CS01
GI system including mouth: Week 56 — Normal10298
GI system including mouth: Week 56 — Abnormal, NCS24
GI system including mouth: Week 56 — Abnormal, CS00
GI system including mouth: Week 82 — Normal9694
GI system including mouth: Week 82 — Abnormal, NCS15
GI system including mouth: Week 82 — Abnormal, CS20
Musculoskeletal system: Week 0 — Normal121119
Musculoskeletal system: Week 0 — Abnormal, NCS47
Musculoskeletal system: Week 0 — Abnormal, CS00
Musculoskeletal system: Week 30 — Normal113106
Musculoskeletal system: Week 30 — Abnormal, NCS310
Musculoskeletal system: Week 30 — Abnormal, CS00
Musculoskeletal system: Week 56 — Normal10297
Musculoskeletal system: Week 56 — Abnormal, NCS15
Musculoskeletal system: Week 56 — Abnormal, CS10
Musculoskeletal system: Week 82 — Normal9792
Musculoskeletal system: Week 82 — Abnormal, NCS17
Musculoskeletal system: Week 82 — Abnormal, CS10
CNS and PNS: Week 0 — Normal124124
CNS and PNS: Week 0 — Abnormal, NCS12
CNS and PNS: Week 0 — Abnormal, CS00
CNS and PNS: Week 30 — Normal115115
CNS and PNS: Week 30 — Abnormal, NCS11
CNS and PNS: Week 30 — Abnormal, CS00
CNS and PNS: Week 56 — Normal104101
CNS and PNS: Week 56 — Abnormal, NCS01
CNS and PNS: Week 56 — Abnormal, CS00
CNS and PNS: Week 82 — Normal9998
CNS and PNS: Week 82 — Abnormal, NCS01
CNS and PNS: Week 82 — Abnormal, CS00
Skin: Week 0 — Normal7658
Skin: Week 0 — Abnormal, NCS4764
Skin: Week 0 — Abnormal, CS24
Skin: Week 30 — Normal7156
Skin: Week 30 — Abnormal, NCS4456
Skin: Week 30 — Abnormal, CS14
Skin: Week 56 — Normal6548
Skin: Week 56 — Abnormal, NCS3553
Skin: Week 56 — Abnormal, CS41
Skin: Week 82 — Normal5750
Skin: Week 82 — Abnormal, NCS4048
Skin: Week 82 — Abnormal, CS21
Thyroid gland: Week 0 — Normal124124
Thyroid gland: Week 0 — Abnormal, NCS12
Thyroid gland: Week 0 — Abnormal, CS00
Thyroid gland: Week 30 — Normal115114
Thyroid gland: Week 30 — Abnormal, NCS12
Thyroid gland: Week 30 — Abnormal, CS00
Thyroid gland: Week 56 — Normal103101
Thyroid gland: Week 56 — Abnormal, NCS11
Thyroid gland: Week 56 — Abnormal, CS00
Thyroid gland: Week 82 — Normal9798
Thyroid gland: Week 82 — Abnormal, NCS21
Thyroid gland: Week 82 — Abnormal, CS00
Lymph node palpation: Week 0 — Normal124125
Lymph node palpation: Week 0 — Abnormal, NCS11
Lymph node palpation: Week 0 — Abnormal, CS00
Lymph node palpation: Week 30 — Normal115116
Lymph node palpation: Week 30 — Abnormal, NCS10
Lymph node palpation: Week 30 — Abnormal, CS00
Lymph node palpation: Week 56 — Normal103102
Lymph node palpation: Week 56 — Abnormal, NCS10
Lymph node palpation: Week 56 — Abnormal, CS00
Lymph node palpation: Week 82 — Normal9898
Lymph node palpation: Week 82 — Abnormal, NCS11
Lymph node palpation: Week 82 — Abnormal, CS00
SecondaryChange in Height SDS

Change in height standard deviation score (SDS) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. Results are based on both participants who completed the trial period, week 0-30, week 0-56 or week 0-82, and participants who could not complete the corresponding trial period, but attended the follow-up visit at week 30, 56 or 82, respectively.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · SDS
Change in Height SDS
SDSLiraglutide 3.0 mgPlacebo
Change from week 0 to week 300.11 ± 0.170.13 ± 0.18
Change from week 0 to week 560.20 ± 0.270.24 ± 0.30
Change from week 56 to week 820.07 ± 0.160.06 ± 0.12
SecondaryChange in C-SSRS

This outcome measure presents number of subjects with "suicidal ideation or suicidal behaviour on the Columbia Suicidality Severity Rating Scale (C-SSRS)" assessed at baseline (week 0), week 30, week 56 and week 82. Week 30, 56 and 82 results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Count of participants · Participants
Change in C-SSRS
ParticipantsLiraglutide 3.0 mgPlacebo
Wk 0: Suicidal ideation22
Wk 0: Suicidal behaviour01
Wk0: Self-injurious behaviour, no suicidal intent01
Wk 30: Suicidal ideation00
Wk 30: Suicidal behaviour00
Wk30: Self-injurious behaviour, no suicidal intent00
Wk 56: Suicidal ideation00
Wk 56: Suicidal behaviour00
Wk56: Self-injurious behaviour, no suicidal intent00
Wk 82: Suicidal ideation00
Wk 82: Suicidal behaviour00
Wk82: Self-injurious behaviour, no suicidal intent00
SecondaryChange in PHQ-9

Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 30 and 56, and from week 56 to week 82. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. Results are based on the participants who completed the corresponding trial period, week 0-30, week 0-56 or week 0-82.

Time frame:
(Week 0, week 30); (Week 0, week 56); (Week 56, week 82)
Reported as:
Mean · Score on a scale
Change in PHQ-9
Score on a scaleLiraglutide 3.0 mgPlacebo
Change from week 0 to week 30-1 ± 4-1 ± 4
Change from week 0 to week 56-1 ± 3-2 ± 3
Change from week 56 to week 820 ± 2-0 ± 3

Adverse events

Collected over Week 0-56 + 14 days. Results are based on the SAS which included all randomised participants exposed to at least one dose of trial product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 3.0 mg1/125 (0.8%)3/125 (2.4%)100/125 (80%)
Placebo0/126 (0%)5/126 (4%)84/126 (66.7%)
Most frequent serious events
Most frequent serious events
EventLiraglutide 3.0 mgPlacebo
Completed suicidePsychiatric disorders1/1250/126
MyositisMusculoskeletal and connective tissue disorders1/1250/126
Post procedural haemorrhageInjury, poisoning and procedural complications1/1250/126
AppendicitisInfections and infestations0/1251/126
Cholecystitis acuteHepatobiliary disorders0/1251/126
CholelithiasisHepatobiliary disorders0/1251/126
Haemorrhagic ovarian cystReproductive system and breast disorders0/1251/126
PneumoniaInfections and infestations0/1251/126
ThrombophlebitisVascular disorders0/1251/126
Most frequent other events
Showing 10 of 16
Most frequent other events
EventLiraglutide 3.0 mgPlacebo
NauseaGastrointestinal disorders53/12518/126
VomitingGastrointestinal disorders43/1255/126
NasopharyngitisInfections and infestations34/12538/126
HeadacheNervous system disorders29/12535/126
DiarrhoeaGastrointestinal disorders28/12518/126
Abdominal pain upperGastrointestinal disorders17/12517/126
GastroenteritisInfections and infestations16/1256/126
Oropharyngeal painRespiratory, thoracic and mediastinal disorders11/12515/126
DizzinessNervous system disorders13/1254/126
InfluenzaInfections and infestations11/12512/126

Baseline characteristics

Results are based on the full analysis set (FAS) which included all randomised participants who had received at least one dose of trial product and had any post-randomisation data (according to the intention-to-treat \[ITT\] principle).

Age, Continuous
Age, Continuous(Years)Liraglutide 3.0 mgPlaceboTotal
Mean14.6 ± 1.614.5 ± 1.614.5 ± 1.6
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 3.0 mgPlaceboTotal
Female7178149
Male5448102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Liraglutide 3.0 mgPlaceboTotal
Hispanic or Latino322456
Not Hispanic or Latino93102195
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Liraglutide 3.0 mgPlaceboTotal
American Indian or Alaska Native011
Asian202
Black or African American14620
Native Hawaiian or Other Pacific Islander000
White105115220
Other448
09

Study locations

33 sites
  • Novo Nordisk Investigational Site
    Meridian, Idaho 83646, United States
  • Novo Nordisk Investigational Site
    Baton Rouge, Louisiana 70808-4124, United States
  • Novo Nordisk Investigational Site
    Baltimore, Maryland 21229, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Novo Nordisk Investigational Site
    Buffalo, New York 14222, United States
  • Novo Nordisk Investigational Site
    Columbus, Ohio 43213, United States
  • Novo Nordisk Investigational Site
    Dayton, Ohio 45406, United States
  • Novo Nordisk Investigational Site
    Dayton, Ohio 45419, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • Novo Nordisk Investigational Site
    Charleston, South Carolina 29425, United States
  • Novo Nordisk Investigational Site
    Goose Creek, South Carolina 29445, United States
  • Novo Nordisk Investigational Site
    Greenville, South Carolina 29615, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38119, United States
  • Novo Nordisk Investigational Site
    Brussels, 1090, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1200, Belgium
  • Novo Nordisk Investigational Site
    Edegem, 2650, Belgium
  • Novo Nordisk Investigational Site
    Hasselt, 3500, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Namur, 5000, Belgium
  • Novo Nordisk Investigational Site
    Ciudad Madero, Tamaulipas 89440, Mexico
  • Novo Nordisk Investigational Site
    Puebla, 72190, Mexico
  • Novo Nordisk Investigational Site
    Moscow, 125373, Russian Federation
  • Novo Nordisk Investigational Site
    Novosibirsk, 630048, Russian Federation
  • Novo Nordisk Investigational Site
    Rostov-on-Don, 344013, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 191144, Russian Federation
  • Novo Nordisk Investigational Site
    Samara, 443079, Russian Federation
  • Novo Nordisk Investigational Site
    Stavropol, 355035, Russian Federation
  • Novo Nordisk Investigational Site
    Tomsk, 634050, Russian Federation
  • Novo Nordisk Investigational Site
    Ufa, 450106, Russian Federation
  • Novo Nordisk Investigational Site
    Göteborg, 416 85, Sweden
  • Novo Nordisk Investigational Site
    Huddinge, 141 57, Sweden
  • Novo Nordisk Investigational Site
    Malmö, 205 02, Sweden
  • Novo Nordisk Investigational Site
    Uppsala, 751 85, Sweden
10

References and documents

Publications

  • Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. N Engl J Med. 2020 May 28;382(22):2117-2128. doi: 10.1056/NEJMoa1916038. Epub 2020 Mar 31. PubMed 32233338 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Feb 2019, 28 months.

Results were first posted in Apr 2020, 1 year 2 months after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 28 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2016
First posted
Sep 28, 2016
StartActual
Sep 29, 2016
Primary completionActual
Feb 14, 2019
CompletionActual
Aug 8, 2019
Results first posted
Apr 27, 2020
Last update
Apr 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02918279
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 28, 2016
Start date
Sep 29, 2016
Primary completion
Feb 14, 2019
Completion
Aug 8, 2019
Results posted
Apr 27, 2020
Last update
Apr 27, 2020

Study contacts

Global Clinical Registry (GCR)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion